48.21
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Bio Techne Corp stock is traded at $48.21, with a volume of 2.52M.
It is up +1.77% in the last 24 hours and down -17.70% over the past month.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
See More
Previous Close:
$47.37
Open:
$47.3
24h Volume:
2.52M
Relative Volume:
0.98
Market Cap:
$7.55B
Revenue:
$1.22B
Net Income/Loss:
$81.07M
P/E Ratio:
93.78
EPS:
0.5141
Net Cash Flow:
$223.02M
1W Performance:
+11.34%
1M Performance:
-17.70%
6M Performance:
-21.65%
1Y Performance:
+1.88%
Bio Techne Corp Stock (TECH) Company Profile
Name
Bio Techne Corp
Sector
Industry
Phone
612-379-8854
Address
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
TECH
Bio Techne Corp
|
48.21 | 7.42B | 1.22B | 81.07M | 223.02M | 0.5141 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-21-25 | Upgrade | Citigroup | Neutral → Buy |
| Jul-22-25 | Resumed | Stephens | Overweight |
| Jul-09-25 | Initiated | TD Cowen | Buy |
| May-30-25 | Initiated | Wells Fargo | Overweight |
| Apr-09-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Mar-18-25 | Initiated | Evercore ISI | Outperform |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-08-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-02-24 | Downgrade | Stifel | Buy → Hold |
| Dec-07-23 | Initiated | UBS | Buy |
| Aug-28-23 | Initiated | William Blair | Outperform |
| Jan-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Sep-15-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-08-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-23-21 | Upgrade | Stifel | Hold → Buy |
| Jan-25-21 | Reiterated | The Benchmark Company | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Jul-15-20 | Downgrade | Stephens | Overweight → Equal-Weight |
| May-27-20 | Downgrade | Stifel | Buy → Hold |
| May-14-20 | Initiated | The Benchmark Company | Buy |
| Jan-08-20 | Resumed | Stephens | Overweight |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-02-19 | Upgrade | Janney | Neutral → Buy |
| Jan-14-19 | Upgrade | Stephens | Equal-Weight → Overweight |
| Oct-31-18 | Downgrade | Craig Hallum | Buy → Hold |
| Oct-17-18 | Initiated | Goldman | Neutral |
| Jun-15-18 | Initiated | Argus | Buy |
| Jul-13-17 | Initiated | Wells Fargo | Market Perform |
| Feb-09-17 | Initiated | Citigroup | Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Jan-21-15 | Reiterated | Robert W. Baird | Outperform |
| Sep-20-13 | Upgrade | Robert W. Baird | Neutral → Outperform |
View All
Bio Techne Corp Stock (TECH) Latest News
Are Wall Street Analysts Bullish on Bio-Techne Stock? - inkl
Bio-Techne Corp (TECH) Stock Analysis: An Investor's Look At 27% Potential Upside - DirectorsTalk Interviews
Bio-Techne Corp. stock outperforms competitors on strong trading day - MarketWatch
Bio-Techne Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Bio-Techne Corp (TECH) Stock Analysis: Unlocking a 41.84% Upside Potential in Healthcare Innovation - DirectorsTalk Interviews
The 5 Most Interesting Analyst Questions From Bio-Techne’s Q1 Earnings Call - Yahoo Finance
Bio-Techne stock hits 52-week low at 44.09 USD - Investing.com India
Bio-Techne stock hits 52-week low at 44.09 USD By Investing.com - Investing.com Australia
Bio-Techne Corp. stock underperforms Friday when compared to competitors - MarketWatch
RBC Capital Mkts resumed coverage on Bio-Techne with a new price target - Quantisnow
Bio-Techne (TECH) Coverage Reinitiated with Positive Outlook - GuruFocus
RBC Capital assumes Bio-Techne stock coverage with outperform rating By Investing.com - Investing.com Australia
RBC Capital assumes Bio-Techne stock coverage with outperform rating - Investing.com UK
Baron Asset Fund Sold Bio-Techne Corporation (TECH) Due to Concerns Over Potential Impact of AI - Yahoo Finance
Bio-Techne Corp. stock underperforms Wednesday when compared to competitors - MSN
There May Be Some Bright Spots In Bio-Techne's (NASDAQ:TECH) Earnings - Yahoo Finance
TECH Stock Price, Quote & Chart | BIO-TECHNE CORP (NASDAQ:TECH) - ChartMill
Bio-Techne (TECH) director’s linked account exercises options and sells 6,636 shares - Stock Titan
Earnings call transcript: Bio-Techne Q3 2026 misses EPS and revenue targets By Investing.com - Investing.com South Africa
Earnings call transcript: Bio-Techne Q3 2026 misses EPS and revenue targets - Investing.com Nigeria
How Bio-Techne is bridging cancer research, spatial biology, and diagnostics - SelectScience
Bio-Techne Corp. stock underperforms Monday when compared to competitors - MarketWatch
Nicholas Company Inc. Acquires 23,785 Shares of Bio-Techne Corp $TECH - MarketBeat
Bio-Techne Corp (TECH) Stock Analysis: Exploring a 29.52% Potential Upside Amidst Market Volatility - DirectorsTalk Interviews
Bio-Techne(TECH) Stock Options Chain | Quotes & News - Moomoo
BIO-TECHNE CORPORATION CMNRo Khanna Congressional Trade on Apr. 13, 2026 - Quiver Quantitative
Responsive Playbooks and the TECH Inflection - Stock Traders Daily
Principal Financial Group Inc. Has $41.37 Million Stock Position in Bio-Techne Corp $TECH - MarketBeat
Bio-Techne Corp (NASDAQ:TECH) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
TECH (TECH) Form 144 shows planned option-exercise sales, prior sale by Molho - Stock Titan
Earnings call transcript: Bio-Techne Q3 2026 results show strategic focus - Investing.com UK
Earnings call transcript: Bio-Techne Q3 2026 results show strategic focus By Investing.com - Investing.com South Africa
Rep. April McClain Delaney Sells Bio-Techne Corp (NASDAQ:TECH) Shares - MarketBeat
April McClain Delaney Makes Significant Trades in Bio-Techne Corp, C.H. Robinson Worldwide, and Transdigm Group - Investing.com UK
Evercore Maintains Bio-Techne(TECH.US) With Hold Rating, Cuts Target Price to $50 - Moomoo
TECH Maintained by Evercore ISI Group -- Price Target Lowered to $50 - GuruFocus
CFO at Bio-Techne (TECH) exercises 62,000 options and settles taxes in shares - Stock Titan
Bio-Techne (TECH) SVP exercises 8,400 options, 7,055 shares withheld for taxes - Stock Titan
Bio-Techne (TECH) CEO exercises options; shares withheld for taxes - Stock Titan
Citigroup Issues Pessimistic Forecast for Bio-Techne (NASDAQ:TECH) Stock Price - MarketBeat
Wells Fargo & Company Cuts Bio-Techne (NASDAQ:TECH) Price Target to $62.00 - MarketBeat
Bio Techne Corp Stock (TECH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):